Epizyme, Inc. (NASDAQ:EPZM)‘s stock had its “outperform” rating reiterated by equities research analysts at Leerink Swann in a research report issued on Wednesday. They currently have a $28.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $31.00. Leerink Swann’s price target points to a potential upside of 112.93% from the company’s current price.

A number of other analysts have also recently weighed in on EPZM. Cann reaffirmed an “outperform” rating and set a $26.00 target price on shares of Epizyme in a research note on Wednesday, April 12th. Oppenheimer Holdings, Inc. initiated coverage on shares of Epizyme in a research note on Thursday, April 13th. They set an “outperform” rating and a $26.00 target price on the stock. CIBC reaffirmed an “outperform” rating on shares of Epizyme in a research note on Thursday, April 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $20.00 target price (up previously from $19.00) on shares of Epizyme in a research note on Wednesday, May 10th. Finally, Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $23.38.

Epizyme (NASDAQ EPZM) traded down 2.59% during midday trading on Wednesday, reaching $13.15. The company had a trading volume of 380,703 shares. The company’s market capitalization is $767.41 million. The stock’s 50 day moving average is $13.88 and its 200 day moving average is $14.28. Epizyme has a one year low of $7.02 and a one year high of $18.50.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. The firm had revenue of $10 million for the quarter, compared to analysts’ expectations of $3.95 million. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 58.97%. The company’s revenue was up 2027.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. Equities research analysts forecast that Epizyme will post ($2.43) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Epizyme, Inc. (NASDAQ:EPZM) Earns “Outperform” Rating from Leerink Swann” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/epizyme-inc-nasdaqepzm-earns-outperform-rating-from-leerink-swann/1466494.html.

In related news, insider Robert A. Copeland sold 2,500 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $13.45, for a total value of $33,625.00. Following the sale, the insider now owns 34,038 shares of the company’s stock, valued at $457,811.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew E. Singer sold 3,024 shares of the business’s stock in a transaction on Friday, June 30th. The stock was sold at an average price of $15.50, for a total transaction of $46,872.00. Following the completion of the sale, the chief financial officer now directly owns 40,529 shares in the company, valued at approximately $628,199.50. The disclosure for this sale can be found here. In the last three months, insiders sold 50,524 shares of company stock worth $746,797. 25.20% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the company. Palo Alto Investors LLC boosted its stake in shares of Epizyme by 57.8% in the first quarter. Palo Alto Investors LLC now owns 4,791,051 shares of the biopharmaceutical company’s stock valued at $82,167,000 after buying an additional 1,755,255 shares in the last quarter. State Street Corp boosted its stake in shares of Epizyme by 49.4% in the fourth quarter. State Street Corp now owns 1,088,635 shares of the biopharmaceutical company’s stock valued at $13,173,000 after buying an additional 359,859 shares in the last quarter. American International Group Inc. boosted its stake in shares of Epizyme by 7.1% in the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock valued at $425,000 after buying an additional 1,638 shares in the last quarter. Woodstock Corp boosted its stake in shares of Epizyme by 5.5% in the second quarter. Woodstock Corp now owns 37,078 shares of the biopharmaceutical company’s stock valued at $560,000 after buying an additional 1,945 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 3,269 shares in the last quarter. 81.30% of the stock is currently owned by institutional investors.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.